Login to Your Account



ArQule Plans $25M Acquisition Of Cyclis To Build R&D Program

By Kim Coghill


Friday, July 18, 2003
Through its planned $25 million purchase of Cyclis Pharmaceuticals Inc., ArQule Inc. will combine a biology-based program with its chemistry-focused technology to build its own research and development business. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription